ReviewCancer chemotherapy and pharmacology2014
GEIS 2013 guidelines for gastrointestinal sarcomas (GIST).
Review in Cancer chemotherapy and pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Giant jejunal gastrointestinal stromal tumor presenting as refractory anemia: a case report of complex R0 resection.International journal of surgery case reports · 2026Article
- Gastrointestinal stromal tumor causing bleeding and intussusception: A case report.International journal of surgery case reports · 2025Article
- Neoadjuvant Imatinib in Gastrointestinal Stromal Tumors (GIST): The First Analysis of a Mexican Population.Cureus · 2024Article
- A giant gastric stromal tumor with dizziness as the main complaint: A case report and literature review.International journal of surgery case reports · 2023Article
- 2023 GEIS Guidelines for gastrointestinal stromal tumors.Therapeutic advances in medical oncology · 2023Review
- An entity that should be kept in mind: Synchronous gastrointestinal stromal tumor encountered in resection materials obtained for the detection of intra-abdominal malignancies.Northern clinics of Istanbul · 2023Article
- Intraperitoneal bleeding and haemorrhagic shock caused by ruptured stomach GIST.Przeglad gastroenterologiczny · 2023Article
- A jejunal gastrointestinal stromal tumor with massive gastrointestinal hemorrhage treated by emergency surgery: A case report.Medicine · 2022Article
- Article
- Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?Sisli Etfal Hastanesi tip bulteni · 2022Article
- Article
- Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.International journal of molecular sciences · 2021Review
- The Relationship betweenReports of biochemistry & molecular biology · 2020Article
- Treatment of a Gastrointestinal Stromal Tumor (GIST) Adherent to the Spleen and the Tail of the Pancreas: A Case Report.The American journal of case reports · 2020Article
- Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.World journal of clinical cases · 2020Review
- Multifocal gastrointestinal stromal tumor: A case report with CT, surgical, and histopathologic correlation.Radiology case reports · 2019Article
- A correlation research of Ki67 index, CT features, and risk stratification in gastrointestinal stromal tumor.Cancer medicine · 2018Article
- Article
- Article
- Correlation between important genes of mTOR pathway (Medical journal of the Islamic Republic of Iran · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal soft tissue sarcoma of the gastrointestinal tract. Correct diagnosis with thorough use of pathologic and molecular tools of GIST mutations has been of the foremost importance. GIST are usually (95 %) KIT positive and harbor frequent KIT or platelet-derived growth factor receptor α-activating mutations. This deep molecular understanding has allowed the correct classification into risk groups with implications regarding prognosis, essential use in the development of targeted therapies and even response prediction to this drugs. Treatment has been evolving and an update to include lessons learned from recent trials in advanced disease as well as controversies in the adjuvant setting that are changing daily practice, is reviewed here. An effort from the Spanish Group for Sarcoma Research with investigators from the group has been undertaken to launch this third version of the GIST guidelines and provide a practical means for the different disciplines that treat this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.